CALL - SPRINTER OPEN END - MODERNA | Market Closed - Euronext Paris 12:30:01 2024-06-14 pm EDT | ||
| 4.055 EUR | -12.98% |
|
| Current month | -2.31% | ||
| 1 month | +36.39% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 4.235 | -9.12% |
| 24-06-13 | 4.66 | -3.32% |
| 24-06-12 | 4.82 | -1.83% |
| 24-06-11 | 4.91 | +2.29% |
| 24-06-10 | 4.8 | -9.26% |
Real-time Euronext Paris
Last update June 14, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| TW61V | |
| ISIN | DE000VD1NHW9 |
| Date issued | 2024-03-08 |
| Strike | 98.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.92 € |
|---|---|
| Lowest since issue | 0.385 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140
USD
Average target price
145.2
USD
Spread / Average Target
+3.67%
- Stock Market
- Certificates
- TW61V Certificat
